Medullary thyroid carcinoma (MTC) is a rare malignancy originating from the calcitoninsecreting parafollicular thyroid C cells. Approximately 75% of cases are sporadic. Rearranged during transfection (RET) proto-oncogene plays a crucial role in MTC development. Besides RET, other oncogenes commonly involved in the pathogenesis of human cancers have also been investigated in MTC. The family of human RAS genes includes the highly homologous HRAS, KRAS, and NRAS genes that encode three distinct proteins. Activating mutations in specific hotspots of the RAS genes are found in about 30% of all human cancers. In thyroid neoplasias, RAS gene point mutations, mainly in NRAS, are detected in benign and malignant tumors arising from the follicular epithelium. However, recent reports have also described RAS mutations in MTC, namely in HRAS and KRAS. Overall, the prevalence of RAS mutations in sporadic MTC varies between 0-43.3%, occurring usually in tumors with WT RET and rarely in those harboring a RET mutation, suggesting that activation of these proto-oncogenes represents alternative genetic events in sporadic MTC tumorigenesis. Thus, the assessment of RAS mutation status can be useful to define therapeutic strategies in RET WT MTC. MTC patients with RAS mutations have an intermediate risk for aggressive cancer, between those with RET mutations in exons 15 and 16, which are associated with the worst prognosis, and cases with other RET mutations, which have the most indolent course of the disease. Recent results from exome sequencing indicate that, besides mutations in RET, HRAS, and KRAS, no other recurrent driver mutations are present in MTC.
ras genes, or H-ras and K-ras. The nucleotide sequences of the H-ras and K-ras oncogenes were not published until 1982 , Tsuchida et al. 1982 .
The molecular cloning of a human transforming gene from the EJ/T24 bladder carcinoma cell line , Pulciani et al. 1982 , Shih & Weinberg 1982 revealed that the molecular basis of HRAS gene activation was a single missense mutation in codon 12, which was also found in the viral H-ras and K-ras genes (Reddy et al. 1982 , Tabin et al. 1982 , Taparowsky et al. 1982 . The mechanism of KRAS activation from lung and colon tumor cells proved also to be the mutation of codon 12 (Capon et al. 1983) . In 1983, a new human transforming gene, not previously found in retroviruses, was identified (Hall et al. 1983 , Shimizu et al. 1983 ) as a third member of the RAS gene family. This gene was discovered in neuroblastomaderived DNA and was named NRAS.
In addition to mutations at codon 12, RAS mutations were later identified at codons 13 and 61. Mutations affecting other regions of the RAS genes have also been found, but at very low frequencies. Therefore, these three codons harbor about 92-98% of all RAS mutations in human cancer and thus represent the hotspots of RAS activation.
The recent identification of germline RAS mutations in a class of genetic syndromes affecting normal development (RASopathies) implicates the aberrant RAS signaling in other human disorders (Tidyman & Rauen 2009 ), and expands the use of anti-RAS drugs, originally designed as anti-cancer therapies, as obvious potential therapies for these distinct developmental disorders.
Mechanism of oncogenic activation
In humans, the three ubiquitously expressed RAS genes encode four distinct but highly homologous w21 kDa proteins (known as p21): HRAS, NRAS, KRAS4A, and KRAS4B (the last two are alternative splice variants of the KRAS gene). These proteins are GTPases that function as molecular switches in regulating pathways that are responsible for diverse cellular processes such as proliferation, differentiation, migration, and apoptosis (Boguski & McCormick 1993) . RAS proteins serve as transducers of signals that connect cell surface receptors to intracellular effector pathways, by switching between 'on' and 'off' conformations, which are conferred by the binding of GTP and GDP respectively. The transition between these two states, under physiological conditions, is regulated both by guanine nucleotide exchange factors, which induce RAS protein activation by promoting GDP for GTP exchange, and by GPTase-activating proteins, which enhances RAS-mediated GTP hydrolysis. The major effect of the most common somatic mutations present in the oncogenic variants of RAS alleles is the maintenance of RAS in the GTP-bound state, with the consequent constant activation of a variety of RAS-dependent downstream effector pathways (Pylayeva-Gupta et al. 2011 ).
Incidence of somatic RAS mutations in human cancer
Oncogenic activation of RAS proteins due to missense mutations is frequently detected in several types of cancer. Different databases have collected all the existing information about specific mutations of RAS genes in different forms of human tumors. For instance, the Wellcome Trust Sanger Institute has launched a catalogue of somatic mutations in cancer (COSMIC) at http://sanger.ac.uk/ cosmic, the most comprehensive database on human tumor mutations currently available (Forbes et al. 2011) .
Based on the data obtained from the COSMIC dataset, 30.1% of all human tumors screened carry some mutation in any of the common RAS genes. KRAS is by far the most frequently mutated isoform, with oncogenic KRAS mutations being detected in 21.2% of all tumors analyzed (29 557 mutated samples of 139 474 samples tested). The frequency of somatic mutations concerning the other family members is much lower, namely 5.7 and 3.2% of samples screened for NRAS (3587 mutated samples of 62 609 samples tested) and HRAS (1127 mutated samples of 35 366 samples tested) respectively. However, these values are biased, because colorectal cancer, where KRAS mutations predominate, represents most of the cases (Prior et al. 2012) . So when all cancer types are given equal weightings, the average pan-RAS mutation incidence is only 14.4% (34 271 mutated samples of 237 449 samples tested).
KRAS mutations are predominant in pancreatic tumors (57.3%) and significantly high percentages are also reported in tumors of the large intestine (34.7%), peritoneum (28.3%), biliary tract (25.2%), small intestine (19.5%), lung (16.9%), endometrium (15.2%), ovary (12.4%), and cervix (7.3%). HRAS mutations are most frequently detected in tumors of the skin (10.0%), salivary gland (9.4%), urinary tract (9.3%), cervix (8.4%), upper aerodigestive tract (7.9%), and penis (7.1%). By contrast, NRAS mutations have higher incidence in tumors of the skin (15.4%), hematopoietic malignancies (9.6%), tumors of the meninges (7.2%), and in thyroid carcinomas (6.2%).
Oncogenic mutations are concentrated within two hotspots (codons 12/13 and 61, which participate in the GTP binding domain of the protein) for all RAS family members. However, the incidence of mutation at both sites varies among the three different main RAS isoforms. For KRAS, the majority of activating mutations are located at codons 12 and 13, which account for 96.3% of the mutations detected (81.9 and 14.4% respectively), whereas mutations affecting codon 61 account for only 1.6%. Although the biological and prognostic significance of other mutations described along this oncogene locus are largely unknown, mutations in exon 4 of KRAS were found to occur commonly and to predict a more favorable clinical outcome in patients with colorectal cancer (Janakiraman et al. 2010) . Another work identified a novel KRAS co-mutation that altered codons 19 and 20, resulting in transitions at both codons (p.Leu19Phe/p. Thr20Ala) in the same allele, in a human colorectal cancer, and demonstrated that co-mutation of these codons is functionally significant (Naguib et al. 2011) . Activating mutations of NRAS show a different distribution pattern, with 60.9% of the mutations occurring at codon 61 and a lower percentage of mutations found at codons 12 (23.4%) and 13 (11.4%). Finally, HRAS mutations follow another specific pattern, with the highest rates of mutation observed in codon 12 (36.7%), followed by codon 61 (34.9%) and codon 13 (20.6%).
Other alternative mechanisms, such as gene amplification, may also lead to RAS activation and contribute to the development of human neoplasia (Pulciani et al. 1985) .
Specific patterns of RAS mutations in thyroid tumors derived from the follicular epithelium
In 1988, activating mutations of all three RAS oncogenes were first described in thyroid tumors (Lemoine et al. 1988 , Suárez et al. 1988 . Early reports demonstrated that the overall rate of RAS mutation in papillary carcinomas was significantly lower than in follicular carcinomas (Wright et al. 1989) . Moreover, the frequency of RAS oncogene activation was similar in benign and malignant thyroid neoplasms, supporting the argument that mutation of RAS oncogenes is an early event in thyroid tumorigenesis (Namba et al. 1990) . Subsequent studies on RAS oncogenes in thyroid tumors showed that most of the published series reported distinct results concerning the incidence of mutations, isoform pattern and correlation of mutations with histology (Vasko et al. 2003) .
RAS mutations are found in a distinct percentage of thyroid cancers (Table 1) . As reported in the current COSMIC somatic mutation database, NRAS mutations are the most frequent RAS mutations in thyroid tumors (6.2%), followed by mutations in HRAS (3.9%) and KRAS (2.0%). RAS mutations have been detected in 40-50% of follicular carcinomas and 20-40% of follicular adenomas, and in oncocytic tumors but at lower frequency (Albarel et al. 2012) . Several studies report that RAS mutations are a marker for aggressive thyroid cancer behavior and poor prognosis (Garcia-Rostan et al. 2003) . In a recent report, RAS mutational analysis was performed in a series of 26 anaplastic thyroid carcinomas (ATCs) and 22 poorly differentiated thyroid carcinomas (PDTCs). In this study, NRAS was the most frequently mutated RAS oncogene isoform (26.9% in ATC and 18.2% in PDTC) and HRAS mutations were only present in ATC (3.8%), and no mutations were observed in KRAS either in ATC or PDTC (Pita et al. 2014) .
RAS mutations have also been detected in medullary thyroid carcinomas (MTCs), and this subject will be further discussed in section 'RAS mutations in MTC'.
Medullary thyroid carcinoma
MTC is a neuroendocrine tumor originating from the calcitonin-producing neural crest-derived parafollicular C cells of the thyroid. They are named C cells due to their calcitonin hormone secretion and account for up to 1% of thyroid cells. These cells are mostly located in the posterior upper third of the lateral lobes of the thyroid gland, where the majority of MTC are found, and they also produce carcinoembryonic antigen (Stamatakos et al. 2011) .
MTC was first described by Jaquet (1906) as 'malignant goiter with amyloid'. Hazard et al. (1959) characterized the medullary carcinoma and recommended its recognition as a distinct clinicopathological entity. Williams (1966) suggested that this tumor is derived from the parafollicular cells. MTC is a relatively rare carcinoma, representing 5-10% of all thyroid cancers, and accounts for up to 14% of all thyroid cancer-related deaths (Roman et al. 2006) , with w1000 new diagnoses in the USA each year (Pacini et al. 2010) . MTC typically grows slowly and metastasizes to cervical and mediastinal nodal chains in up to 50% of cases. It also metastasizes to distant organs such as the lungs, liver, and bones in 20% of cases . MTC is classically managed with surgery and, unlike DTC, MTC is not iodine avid and treatment with radioactive iodine is not indicated. Moreover, the prognosis of MTC is intermediate between well-DTC and ATC, being less favorable than that of papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma.
The 10-year overall survival rate of MTC is about 75% (Hundahl et al. 1998 ), but it decreases to 40% or less in patients with locally advanced or metastatic disease . Important prognostic factors that predict adverse outcome include advanced age at diagnosis, extent of primary tumor, nodal disease, and distant metastases (American Thyroid Association Guidelines Task Force et al. 2009). The occurrence of locoregional and distant metastases occurs preferentially within the first 5 years (Peixoto Callejo et al. 2006 ). There has been limited success in the use of systemic chemotherapy or radiotherapy to treat patients with metastatic MTC (Martins et al. 2006) . Surgical removal of all malignant tissue performed at an early stage, when the disease is confined to the thyroid gland, is the only potentially curative treatment, and management guidelines for treatment of MTC were published by the American Thyroid Association (American Thyroid Association Guidelines Task Force et al. 2009).
MTC occurs in either sporadic (75%) or hereditary (25%) form, and is transmitted in an autosomal dominant pattern with a nearly 100% level of penetrance (Ponder et al. 1988) , either as familial MTC without other endocrinopathies or as part of the multiple endocrine neoplasia (MEN) syndromes types 2A and 2B. The most aggressive variant of MTC is MEN2B. Since the seminal description by Wolfe et al. (1973) , C-cell hyperplasia (CCH) has become recognized as a precursor to malignant transformation. Individuals affected with inherited MTC develop initially primary CCH that progresses to early invasive medullary microcarcinoma, and eventually evolves into grossly invasive macroscopic MTC. Familial forms often appear as multifocal and bilateral tumors developing at a young age (Schulten et al. 2011) , whereas in sporadic cases, the tumor is usually unifocal and discovered in the fifth or sixth decade of life (Heshmati et al. 1997) . At diagnosis, patients with sporadic MTC most commonly present with an isolated thyroid nodule or a palpable cervical lymph node.
The rearranged during transfection (RET) protooncogene is the susceptibility gene for hereditary MTC. The RET gene was first identified in 1985 (Takahashi et al. 1985) , and in 1993 and 1994 it was demonstrated that MEN2 syndromes were caused by germline RET mutations (Donis-Keller et al. 1993 , Eng et al. 1994 . Thus, constitutively activating RET point mutations occurring germline are present in virtually all patients with inherited MTC (Kouvaraki et al. 2005) . The RET gene, composed of 21 exons, is mapped to chromosome 10q11.2 and encodes a tyrosine kinase receptor with a cysteine-rich extracellular domain, a transmembrane domain and an intracellular portion containing two tyrosine kinase domains. The RET gene plays a crucial role in regulating cell proliferation, migration, differentiation, and survival (Eng 1999) .
RET mutations involved in MTC are gain-of-function alterations that increase RET kinase activity, resulting in a constant activation of several intracellular signaling cascades that lead ultimately to tumor growth. Several germline mutations of this gene have been associated with hereditary MTC and a strong genotype-phenotype correlation has been reported, with mutations in exons 10 or 11 occurring mainly in individuals with MEN2A and the p.Met918Thr mutation in exon 16 being found in the majority of MEN2B cases . The presence of specific RET mutations determines the age of presentation and aggressiveness of the tumor (Cote & Gagel 2003) . Point mutations in the RET gene cluster in exons 5, 8, 10, 11, 13-16, and exons 5 and 8 have been added recently to the routine panel of studied exons in MTC (Romei et al. 2011 ). Identification of a RET germline mutation is the definitive method to distinguish sporadic from inherited forms. RET molecular analysis is essential in MTC management, since early diagnosis improves prognosis and allows genetic screening and recommendations for prophylactic thyroidectomy in familial cases (American Thyroid Association Guidelines Task Force et al. 2009).
Although much is known about hereditary MTC, the oncogenic mechanisms underlying sporadic MTC are not so well characterized. Molecular studies have demonstrated the involvement of RET proto-oncogene in 12-100% of the sporadic forms of MTC, depending on the reported series (Moura et al. 2009 ). p.Met918Thr RET mutation is the most common mutation in sporadic MTC but its detection rate varies greatly (5-66%) in the published literature (Moura et al. 2009 ).
Somatic RET mutations have been correlated with a worse outcome (Ciampi et al. 2013 ) and associated with larger tumors, lymph node and distant metastases, more advanced stage at diagnosis and low overall survival, as well as male gender and young age at diagnosis (Dvorakova et al. 2008 , Elisei et al. 2008 , Mian et al. 2011 ). However, there are studies reporting no statistically significant association between clinical and pathological characteristics, and the presence or absence of somatic RET mutations (Tamburrino et al. 2012 , Lyra et al. 2014 .
In a recent study (Moura et al. 2009 ), somatic RET mutations were correlated with clinicopathological features of sporadic MTC and the results suggested a stratification of sporadic MTC patients into risk levels: patients with mutations in RET exons 15 and 16 were at the highest risk for aggressive MTC, followed by those having no detectable RET mutation, at intermediate risk, and patients bearing other RET mutations, who presented the lowest risk for a worse clinical outcome. Therefore, this study showed that RET mutations in exons 15 and 16 are associated with a more aggressive behavior than other RET mutations, as it has been shown in vitro, as well as in the hereditary variants of MTC.
Molecular alterations beyond RET mutations in MTC

Copy number alterations
Fluorescence in situ hybridization and real-time quantitative PCR revealed RET copy number alterations (CNA) in 27.7% MTC, represented either by RET gene amplification (exclusively in hereditary MTC) or chromosome 10 aneuploidy (more frequently observed in sporadic cases). These alterations were present in a variable percentage of cancer cells, suggesting a certain degree of tumoral heterogeneity in MTC. Moreover, a significant higher prevalence of RET CNA was observed in RET mutated MTC and correlated with a poor prognosis (Ciampi et al. 2012) . Using array comparative genomic hybridization in primary tumors and metastases, it was shown that most MTC have only a few copy number changes (most commonly losses of chromosomes 1p, 4q, 19p, and 22q) and some (w23%) do not even present any chromosomal gains and losses, indicating that, unlike most other tumor types (Pinkel & Albertson 2005) , copy number changes in MTC are relatively rare (Flicker et al. 2012) .
Gene and protein expression profile
Concerning protein expression profiling, one study assessed nuclear factor-kB (NF-kB) in a series of MTC in correlation with RET mutation status. NF-kB is a transcription factor implicated in a wide variety of cellular processes including cell growth, differentiation, and apoptosis and is known to be activated through several signaling pathways that involve growth factor receptors. NF-kB expression was more frequently altered in MTC with germline or somatic RET mutations than in cases without RET mutations, supporting the hypothesis that RET activation may be responsible for NF-kB overexpression in MTC (Gallel et al. 2008) . Sponziello et al. (2014) analyzed the expression levels of several genes involved in the epigenetic control of transcription by TaqMan low density arrays in a series of 54 MTC (13 familial and 41 sporadic, 33 carrying a RET mutation, and 13 a RAS somatic mutation). In this study, only overexpression of the histone acetyltransferases KAT2A and KAT2B and of histone demethylase KDM5B was observed in RAS-mutated compared to WT tumors. By contrast, RET-mutated tumors (both germline and somatic) showed higher transcript levels of many epigenetic regulators than both WT and RAS-mutated MTC; significant differences were detected in the expression levels of HDAC3, 6, 7, 8 and 10, EP300, KAT2A and B, SMYD4, CARM1, EHMT1, KDM1A, 2A, 4A, 4C and 5B, DNMT1 and 3A. In the more aggressive MTC cases (i.e., occurrence of lymph node and distant metastases, persistent disease after primary treatment and diseaserelated death), the expression profiling revealed a significant increase of the histone methyltransferases EZH2 and SMYD3 expression, but no significant correlation was found with RET or RAS mutational status; however, a comparison with type or risk level of RET mutations was not performed.
MicroRNA
Dysregulation in microRNA (miRNA) expression has recently been implicated in the pathogenesis of many types of human cancers, including MTC (Nikiforova et al. 2008) . In a series of 19 MTC, a signature of three miRNA (miR-183, miR-375, and miR-9*) enabled to distinguish familial from sporadic cases (Abraham et al. 2011) . Mian et al. (2012) analyzed the expression of nine miRNA (miR-21, miR-127, miR-154, miR-224, miR-323, miR-370, miR-9*, miR-183, and miR-375) in 34 sporadic MTC and correlated this expression with RET status. From the whole set of nine miRNA, only miR-127 was significantly associated with RET status, with sporadic MTC carrying somatic RET mutations showing a lower upregulation of this miRNA than those with a WT RET. No relationships with RAS somatic mutation were observed.
The oncomiR miR-21 specifically targets the tumor suppressor gene PDCD4, and recent studies suggest that PDCD4 is also regulated by protein kinase B (AKT) . In a large series of 64 MTC (56 sporadic and eight familial), Pennelli et al. (2015) demonstrated significant PDCD4 nuclear downregulation together with miR-21 upregulation, thus confirming their previous results obtained in a small series of MTC (Mian et al. 2012) , and showed also that miR-21/PDCD4 expression correlates with clinicopathological findings and prognosis. Although these authors were unable to detect any significant correlation between the miR-21/PDCD4 pathway and somatic RET or RAS mutation status, they found that the six RAS-positive cases in their series of MTC sporadic tumors had higher nuclear PDCD4 expression levels than the RET-positive/RAS-negative or RET/RAS WT patients. RAS-positive cases also revealed an intense reactivity pattern for phospho-AKT on western blot analysis, indicating a preferential activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. It has been shown that phosphorylation of PDCD4 by AKT causes nuclear translocation and inhibits tumor suppressor function of PDCD4 (Palamarchuk et al. 2005 ), suggesting that in RAS-positive tumors PDCD4 is hypofunctional due to the interference of AKT.
In a recent study, the expression of four main genes involved in miRNA biogenesis (DROSHA, DICER, DGCR8, and XPO5) was investigated in a series of 54 MTC analyzed for RET and RAS mutations . Overexpression of DICER, DGCR8, and XPO5 was observed only in RET-mutated tumors (familial or sporadic) compared to RET WT, while RAS-mutated MTC did not show significant differences with respect to non-mutated tumors. When MTC with RET and RAS mutations were compared, only DGCR8 was significantly overexpressed in RET-mutated tumors.
Taken together, miRNA may be useful as prognostic markers and represent new potential targets for a RNAbased therapy in the treatment of MTC.
Gene mutations
Few non-RET molecular alterations have been reported in MTC ( Fig. 1 ). Of note, mutations in TP53 and RB1 are highly uncommon or absent in MTC (Yana et al. 1992 , Yoshimoto et al. 1992 , Herfarth et al. 1997 . Some studies showed the presence of somatic loss of function mutations in the cell cycle inhibitor CDKN2C (p18 INK4C ) in about 10% of human MTC, coexisting with activating RET mutations, and concluded that loss of function of this tumor suppressor gene contributes to RET-induced MTC development (van Veelen et al. 2009 ); however, other authors did not find CDKN2C mutations in MTC samples (Cerrato et al. 2009 ). Our group also looked for mutations in CDKN1B (p18 INK4C ) and CDKN2C (p27 KIP1 ) genes in RET WT sporadic MTC patients and, Summary of the most frequently mutated genes in MTC. The graph represents the genes that are mutated in at least two samples, or only in a single sample but after being tested in more than 100 MTC.
The data relate to the COSMIC v68 release, at http://sanger.ac.uk/cosmic (accessed May 2014).
except for an unreported germline CDKN2C variant (p.Pro117Ser) detected in one patient carrying a somatic HRAS mutation (p.Gly13Arg), no other mutations were found; no mutations were detected in VHL gene either in our series (M M Moura, B M Cavaco and V Leite, unpublished observations), although one (Koch et al. 2006 ) and two (Koperek et al. 2011 ) somatic VHL mutations have been previously described in hereditary and sporadic MTC respectively. Many other oncogenes usually involved in the pathogenesis of various tumor types have been investigated in MTC with little success (Cerrato et al. 2009 ). MTC showed no genetic changes in c-myc, N-myc, and c-erbB proto-oncogenes (Yang et al. 1990 ), such as found commonly in human neoplasms, and absence of missense mutations of Gsa and Gi2a genes has also been observed in MTC (Horie et al. 1995) . EGFR and JAK2 mutations, genetic alterations that constitute potential therapeutic targets for drug-designed inhibitors in lung adenocarcinomas and myeloproliferative disorders, respectively, are infrequent or absent in MTC (Ameur et al. 2009 ). Similarly, mutations in AKT1 and CTNNB1 genes, which are key regulators of the PI3K/AKT/mTOR and canonical Wnt/b-catenin pathways, respectively, are virtually unknown in MTC (Schulten et al. 2011) . Our group found no evidence of mutations in AKT1, AKT2, and AKT3 within hotspots in sporadic MTC (M M Moura, B M Cavaco and V Leite, unpublished observations).
Point mutations in genes frequently implicated in thyroid tumorigenesis and linked to the RET pathway, such as BRAF and PIK3CA, have also been investigated in MTC in limited case series (Xing 2005 , Ameur et al. 2009 ). PIK3CA gene has been screened in 13 cases in a single study and neither mutations nor amplification were found (Wu et al. 2005) . Our group confirmed that mutations in PIK3CA, within the classical hotspots, are absent in RET WT sporadic MTC patients (M M Moura, B M Cavaco and V Leite, unpublished observations). No BRAF gene mutations have been reported in three small series of 13 , 14 (Xing et al. 2004) , and 25 (Perren et al. 2004 ) MTC respectively. However, in a Greek cohort of 44 sporadic MTC, BRAF mutations were detected in 68.2% of the samples (Goutas et al. 2008 ), a finding that was not confirmed in the most recent studies , Moura et al. 2011 , Rapa et al. 2011 , Schulten et al. 2011 , Boichard et al. 2012 , Nikiforova et al. 2013 .
Recently, it was shown that mutations in the promoter region of TERT are relatively frequent in specific types of human cancers, including PTC and ATC (Vinagre et al. 2013) ; however, no mutations were detected in MTC (Killela et al. 2013 , Vinagre et al. 2013 , nor in normal thyroid and benign lesions (such as goiters, adenomas, or thyroiditis).
RAS mutations in MTC
The presence of RAS mutations in sporadic MTC is not entirely unexpected, since Johnston et al. (1998) demonstrated the development of MTC in rascal transgenic mice expressing v-Ha-ras under the control of the calcitonin/ calcitonin gene-related peptide promoter. Also, the expression of transfected v-Ha-ras in MTC cell lines was previously shown to induce neuroendocrine differentiation in vitro (Nakagawa et al. 1987) .
We performed sequencing analysis of the RAS genes in 66 sporadic MTC, 40 with RET mutation and 26 with RET WT, and somatic HRAS and KRAS mutations were detected in 15/26 (57.7%) and 3/26 (11.5%) of RET WT cases respectively (Moura et al. 2011 ; an additional sporadic MTC case was included in this series, M M Moura, B M Cavaco and V Leite, unpublished observations). Only 1/40 (2.5%) RET-positive cases had a somatic RAS mutation, namely in HRAS (p.Gly13Val). Overall, RAS mutations were present in 69.2% (18/26) of the RET WT cases and in only 2.5% of the RET-positive sporadic MTC (P!0.0001), suggesting that activation of the protooncogenes RAS and RET represents alternative genetic events in sporadic MTC tumorigenesis. These results were confirmed by other groups , Schulten et al. 2011 , Boichard et al. 2012 , Mian et al. 2012 , Tamburrino et al. 2012 , Ciampi et al. 2013 , Nikiforova et al. 2013 , Lyra et al. 2014 , Simbolo et al. 2014 , Pennelli et al. 2015 . We found no other mutations in the entire coding region of the genes HRAS, KRAS and RET in the RET and RAS WT sporadic MTC (M M Moura, B M Cavaco and V Leite, unpublished observations).
A comprehensive review of the studies that were published in the literature concerning the prevalence of RAS point mutations in sporadic MTC is shown in Table 2 . The prevalence of RAS mutations in such cases varies between 0-41.2 and 0-40.9% for HRAS and KRAS, respectively, and between 0-1.8% for NRAS, depending on the reported series.
The most frequent HRAS mutation is p.Gln61Arg (nZ35), followed by p.Gln61Lys (nZ20) and p.Gly13Arg (nZ12), whereas the prevalent KRAS mutation is p.Gly12Arg (nZ13). Since not all series analyzed all RAS isoforms, we present in Table 3 the overall prevalence of RAS mutations in the studies where all RAS isoforms were screened. As shown, the prevalence in these studies varies between 0-43.3%. Boichard et al. (2012) screened the somatic mutational status of RAS genes in a series of 50 MTC, including 30 sporadic cases, and three mutations were detected in exon 4 both of HRAS (nZ1, codon 117) and KRAS (nZ2, codon 146). Mian et al. (2012) reported a p.Met72Ile mutation in exon 3 of the HRAS gene in a case with sporadic MTC.
There are several reasons that may explain the different prevalences of RAS point mutations that have been reported in MTC and that are summarized in Tables 2  and 3 . First, in some of the studies, only the three mutational hotspots (codons 12, 13, and 61) were analyzed and/or not all RAS isoforms were screened. Secondly, the sizes of the published series differ substantially. Thirdly, different methodologies, with variable sensitivities for mutation detection, were used for the screening of RAS mutations. Fourthly, ethnic or environmental factors may also account for the reported differences in the prevalence of RAS mutations. Agrawal et al. (2013) sequenced the exomes of 17 sporadic MTC and validated the frequency of all recurrently mutated genes and other genes of interest in an independent cohort of 40 MTC (21 hereditary and 19 sporadic). Wholeexome sequencing revealed that RET was somatically mutated in 12 sporadic MTC in the discovery screen, but no HRAS and KRAS mutations were detected. Other than RET, the genes that were mutated in at least two of the 17 MTC were MDC1, SF3B1, MGAM, DOCK9, SEMA6A, TDG, and DISP2 (see Fig. 1 ). RET, HRAS, and KRAS genes were sequenced in additional 40 MTC (validation screen), and seven HRAS and two KRAS somatic mutations were detected. Thus, recent results from whole-exome sequencing indicate that MTC harbor relatively few mutations overall and suggest that there are no recurrent driver mutations other than RET, HRAS, and KRAS in these tumors. Simbolo et al. (2014) examined the mutational status of 50 cancer-associated genes using a targeted nextgeneration sequencing (NGS) approach in a series of 20 sporadic MTC, previously analyzed for RET mutations by Sanger sequencing. Thirteen MTC harbored a somatic RET mutation; three of them, undetected by Sanger, were revealed by NGS, showing that targeted NGS has a higher sensitivity in the detection of mutations (these cases presented a proportion of RET mutated alleles below the 20% detection limit of Sanger analysis). One of the 13 RETmutated cases also had a p.Phe354Leu germline mutation in STK11, which has been found in Peutz-Jeghers syndrome (Forcet et al. 2005) . Four of the seven RET WT MTC carried a RAS mutation (three in HRAS and one in KRAS) and the three remaining cases were WT for all the 50 cancer-related genes. Thus, beside RET, HRAS, and KRAS mutations, no case exhibited somatic mutations in the other 47 genes studied.
As shown in Table 4 , the prevalence of RAS mutations in different series of sporadic RET WT MTC varies between 0-81.3% (0-77.8, 0-31.3, and 0-2.8% for HRAS, KRAS, and NRAS respectively). HRAS is the gene most frequently affected, followed by KRAS, while mutations in NRAS remain a rare event. This contrasts with tumors arising from the thyroid follicular cells, where NRAS predominates (Vasko et al. 2003 . All the studies where RET and RAS were investigated in MTC showed mutual exclusivity between RET and RAS point mutations , Moura et al. 2011 , Schulten et al. 2011 , Boichard et al. 2012 , Mian et al. 2012 , Tamburrino et al. 2012 , Ciampi et al. 2013 , Nikiforova et al. 2013 , Lyra et al. 2014 , Simbolo et al. 2014 , Pennelli et al. 2015 . However, a somatic HRAS mutation was detected in one RET-positive case in the series of Moura et al. (2011) , and to the best of our knowledge there are no other studies describing RAS mutations in RET-positive MTC. The two MTC patients who harbored NRAS mutations in the series of Ciampi et al. (2013) also presented a concomitant PTC.
RAS analyses performed in peripheral blood or normal thyroid tissue, from MTC cases harboring a RAS mutation in tumoral tissue, were negative indicating the somatic origin of the mutation. This result was expected, as germline HRAS mutations are associated with Costello's It has already been demonstrated that the mTOR pathway is activated in sporadic and hereditary MTC (Rapa et al. 2011 , Tamburrino et al. 2012 ) with a preferential expression in cases with germline RET mutations (Rapa et al. 2011 ). However, it remains unknown whether RAS mutations can also lead to the activation of this signaling pathway in MTC. Lyra et al. (2014) evaluated mTOR activation in a series of 87 MTC (ten familial and 77 sporadic), and RAS mutations were significantly associated with higher intensity of phospho-S6 ribosomal protein (p-S6) (a downstream effector of mTOR) expression; a significantly lower cytoplasmic expression of PTEN (a mTOR inhibitor) was observed in WT RAS cases in comparison with those with RAS Besides our study, only a few others that performed mutational analysis (see Table 2 ) have correlated genotype with patient clinical findings. Ciampi et al. (2013) correlated the RAS mutation status in RET-negative sporadic MTC with the clinical and pathological parameters (sex, age at diagnosis, T categories, size of tumor, lymph node metastases, distant metastases, stage, and status of the disease) of the patients and no statistically significant differences were observed. However, a higher but not statistically significant prevalence of disease-free survival was found in the RAS-mutated group, suggesting that MTC harboring a RAS mutation represent a subgroup of tumors with a less aggressive behavior.
In the study of Simbolo et al. (2014) , clinical follow-up and serum calcitonin levels indicated that at the end of follow-up seven of 12 RET-mutated MTC patients had relapsed (six of them harbored the p.Met918Thr mutation), while the four RAS-mutated cases were disease free; two of the three patients with MTC WT for all 50 genes also relapsed during the follow-up period. No significant association was observed between tumor recurrence and clinicopathological/molecular features. Thus, although not fully demonstrated, it seems that RAS is probably related to a less aggressive phenotype with a better outcome, and the detection of mutations by NGS may improve the diagnostic stratification of sporadic MTC. Goutas et al. (2008) found no significant association between KRAS and BRAF mutations and clinicopathological parameters (age, gender, tumor size, stage, or nodal metastasis) in sporadic MTC. Similarly, in the study of Tamburrino et al. (2012) neither the presence nor the type of RET and RAS mutation was correlated with gender, age, histological variant (spindle cells, epithelioid), or other histological features (fibrosis, amyloid, or necrosis). Lyra et al. (2014) attempted to correlate RAS and RET genotype results and clinicopathological data (gender, age, tumor size, nodal metastasis, invasion, or amyloid stroma) and did not disclose any associations with any clinicopathological feature for RAS-mutated cases; except for MTC patients displaying germline RET mutations that were younger than those with a somatic RET mutation or no RET mutation at all, no other significant association was observed between RET mutations and gender, tumor size, nodal metastasis, invasive features, or presence of amyloid stroma.
RAS mutations as a therapeutic target in MTC
Research over the last several years has enabled a good understanding of the genetic defects and altered molecular pathways that are involved in MTC development, and several promising therapeutic agents that target these specific alterations have been designed to treat advanced or metastatic MTC (Fig. 2) (Giunti et al. 2013 , Haraldsdottir & Shah 2014 .
Patients with progressive MTC have been treated in the last years with small molecule tyrosine kinase inhibitors (TKI), with remarkable results (Hu et al. 2014) . Some studies are targeting the RAS pathway, e.g., through the use of farnesyltransferase inhibitors (FTI), which block the main post-translational modification of the RAS protein, thus interfering with its localization to the inner surface of the plasma membrane and subsequent activation of downstream effectors (Caponigro et al. 2003) . Although initially developed as an approach to target RAS in cancer, FTI have later been recognized as acting by additional and more complex mechanisms, involving RhoB, centromere-binding proteins and probably other farnesylated proteins. Hong et al. (2008) reported on a patient with sporadic MTC with metastatic disease, who was treated with a combination of sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor) and tipifarnib (inhibitor of RAS farnesylation), which resulted in a marked clinical response. In a phase I study, it was shown that combining the multikinase inhibitor sorafenib with the FTI tipifarnib resulted in significant activity, particularly in patients with RET mutations (Hong et al. 2009 ). More recently, Hong et al. (2011) reported a phase I trial where 13 patients with MTC, eight of them (61.5%) carrying germline or somatic RET mutations, were treated with sorafenib combined with tipifarnib. MTC partial response rate was 38.5% (5/13) and stable disease of at least 6 months was 30.8% (4/13). Unfortunately, RAS mutation status was not analyzed in these studies. Sherman et al. (2013a,b) investigated the association of RET and RAS mutations with efficacy outcomes in the phase III study of cabozantinib in MTC (Schöffski et al. 2012) . Cabozantinib is a potent inhibitor of MET, VEGFR2, and RET (Hoy 2014 ). Sixteen of 85 tested patients (5% of total study patients) with WT or unknown RET status were found to harbor a RAS gene mutation and these patients presented a similar tumor response rate (31%) and progression-free survival (47 weeks) as RET-mutated patients (32% and 60 weeks).
Recently, it has been demonstrated that the expression of key TKI target proteins varies in MTC according to the specific RET mutation present (Rodríguez-Antona et al. 2014), a finding that could be used to improve the clinical response of MTC patients. However, the variable response to treatment with TKI remains largely unexplained and little is known about which patients would most benefit from a particular drug therapy. Mancikova et al. evaluated the influence of RAS mutations on the expression levels of eight key TKI targets (EGFR, KIT, MET, PDGFRB, VEGF, VEGFR1, VEGFR2, and VEGFR3) in a series of 84 molecularly characterized primary MTC tumors (27 familial and 57 sporadic). In contrast to RET-mutated tumors, RAS-positive MTC did not express MET and PDGFRB, and stained less frequently for VEGFR3; furthermore, WT tumors expressed VEGF more often than both RASand RET-mutated tumors (Mancikova et al. 2014) . According to these authors, the differences in drug response observed in the study of Sherman et al. (2013a,b) , namely longer progression-free survival for RET-mutated patients treated with cabozantinib when compared with RAS-mutated patients (60 weeks vs 47 weeks), could be explained, at least in part, by the differential expression of cabozantinib targets, as the RASmutated group expresses less often important targets of this drug.
These findings suggest that the assessment of RAS mutation status in sporadic RET-negative MTC can be useful to develop personalized targeted therapies. In conclusion, analysis of RET and RAS mutations in sporadic MTC can be of value both for prognostic purposes and for therapeutic strategies.
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